secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001711279-24-000055
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q3 net product rev $83.8M; VYJUVEK approvals reach 460; JNDA filed in Japan
--------------------------------------------------------------------------------

- Net product revenue of $83.8M from VYJUVEK; $250.1M total since Aug 2023 launch.
- Net income $27.2M ($0.91 diluted) vs $80.7M ($2.79) in Q3 2023; SG&A rose to $28.7M.
- Cash and investments $694.2M; 460+ U.S. reimbursement approvals secured as of October.
- JNDA filed for B-VEC in Japan; EMA decision expected before year end; French early access approved.
- Guidance: non-GAAP R&D+SG&A $115-125M for FY2024; key pipeline data due by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000055/0001711279-24-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000055/krys-20241104.htm
  HTML page:      https://secwatch.observer/filing/0001711279-24-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer